Olema Pharmaceuticals, Inc.

Equities

OLMA

US68062P1066

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 03/06/2024 BST			5-day change	1st Jan Change
11.76 ^USD	+21.36%		+29.80%	-16.18%

05-15	Olema Pharmaceuticals, Inc. Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 Esmo Breast Cancer Congress	CI
05-08	Olema Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Olema Oncology Announces Appointment of Ian T. Clark and Cynthia M. Butitta to Board of Directors

September 10, 2020 at 01:30 pm

Olema Oncology announced it has expanded its Board of Directors with the addition of Ian T. Clark and Cynthia M. Butitta. Mr. Clark will serve as Board Chair and Ms. Butitta will serve as Audit Committee Chair.

Latest news about Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc. Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 Esmo Breast Cancer Congress	05-15	CI
Olema Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Goldman Sachs Initiates Olema Pharmaceuticals at Buy With $24 Price Target	04-02	MT
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to S&P Biotechnology Select Industry Index	03-17	CI
HC Wainwright Adjusts Price Target on Olema Pharmaceuticals to $25 From $28, Maintains Buy Rating	03-12	MT
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-11	CI
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	03-11	CI
Olema Oncology Announces Publication of Data Highlighting Palazestrant?s Ability to Inhibit Wild-Type and Mutant Er+ Breast Cancer Both as Monotherapy and in Combination with Cdk4/6 Inhibitors	03-06	CI
Citigroup Initiates Olema Pharmaceuticals at Buy With $20 Price Target	01-30	MT
Olema Pharmaceuticals, Inc. Nominates OP-3136, an Orally Bioavailable KAT6 Inhibitor, as a Development Candidate	01-08	CI
Olema Pharmaceuticals, Inc.(NasdaqGS:OLMA) added to NASDAQ Biotechnology Index	12-18	CI
Olema Pharmaceuticals, Inc. Announces Palazestrant Demonstrates Attractive Combinability with Cdk4/6 Inhibitors Ribociclib and Palbociclib in Phase 1B/2 Studies	12-05	CI
Transcript : Olema Pharmaceuticals, Inc. Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-29-2023 01:20 PM	11-29
Olema Pharmaceuticals Insider Sold Shares Worth $269,656, According to a Recent SEC Filing	11-24	MT
Olema Pharmaceuticals Insider Sold Shares Worth $824,134, According to a Recent SEC Filing	11-24	MT
Olema Pharmaceuticals Insider Sold Shares Worth $196,233, According to a Recent SEC Filing	11-24	MT
Olema Pharmaceuticals Insider Sold Shares Worth $209,296, According to a Recent SEC Filing	11-24	MT
Olema Pharmaceuticals Insider Sold Shares Worth $117,740, According to a Recent SEC Filing	11-24	MT
Olema Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-07	CI
Olema Pharmaceuticals Insider Sold Shares Worth $379,450, According to a Recent SEC Filing	11-03	MT
JPMorgan Adjusts Olema Pharmaceuticals' Price Target to $25 From $19, Maintains Overweight Rating	24/10/23	MT
Canaccord Genuity Adjusts Olema Pharmaceuticals' Price Target to $22 From $16, Maintains Buy Rating	24/10/23	MT
Olema Pharmaceuticals, Inc. Announces Positive Phase 2 Monotherapy Clinical Study Results for Palazestrant	23/10/23	CI
Olema Pharmaceuticals, Inc. Appoints Scott Garland to Its Board of Directors	17/10/23	CI
Olema Pharmaceuticals, Inc. Announces Phase 2 Monotherapy Clinical Results to Be Presented At the 2023 Esmo Congress	16/10/23	CI

Chart Olema Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of targeted therapies for women's cancers. Its lead product candidate, OP-1250, is an oral therapy with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). The Company's OP-1250 is an oral small molecule clinical-stage product candidate for the treatment of endocrine-driven cancers. OP-1250, both as a monotherapy and in combination with inhibitors of cyclin-dependent kinase four and six (CDK4/6) demonstrated robust tumor shrinkage in several xenograft models, including ESR1 and PIK3CA mutations and central nervous system (CNS), metastasis. It is in the Phase I/ II clinical trial, and in Phase Ib/ II combination with palbociclib, in patients with metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

Sector

Biotechnology & Medical Research

Calendar

05/06/2024 - Jefferies Global Healthcare Conference - Fireside Chat

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.76 USD

Average target price

26.88 USD

Spread / Average Target

+128.53%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
OLEMA PHARMACEUTICALS, INC.	-16.18%	657M
MODERNA, INC.	+48.64%	56.65B
IQVIA HOLDINGS INC.	-6.44%	39.44B
LONZA GROUP AG	+37.21%	39.03B
ICON PUBLIC LIMITED COMPANY	+14.28%	26.75B
CELLTRION, INC.	-11.17%	26.86B
ALNYLAM PHARMACEUTICALS, INC.	-21.40%	19.03B
UNITED THERAPEUTICS CORPORATION	+25.64%	12.26B
BIO-TECHNE CORPORATION	+0.96%	12.28B
MEDPACE HOLDINGS, INC.	+27.04%	12.04B

Other Biotechnology & Medical Research